Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- First Hospital of China Medical University
- Target Recruit Count
- 1354
- Registration Number
- NCT04666805
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 138
- Registration Number
- NCT04556773
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT04553770
- Locations
- 🇺🇸
St. Joseph Heritage Healthcare, Fullerton, California, United States
🇺🇸Cancer Blood and Specialty Clinic, Los Alamitos, California, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT04469764
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
- Conditions
- Interventions
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 221
- Registration Number
- NCT04436744
- Locations
- 🇺🇸
UCLA - Burbank, Burbank, California, United States
🇺🇸UCLA Hematology/Oncology-San Luis Obispo, San Luis Obispo, California, United States
🇺🇸Orlando Health Inc., Orlando, Florida, United States
Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Instituto Jalisciense de Cancerologia
- Target Recruit Count
- 300
- Registration Number
- NCT04389424
- Locations
- 🇲🇽
Instituto Jalisciense de Cancerologia, Guadalajara, Jalisco, Mexico
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 161
- Registration Number
- NCT04294225
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2020-02-10
- Target Recruit Count
- 760
- Registration Number
- NCT04258163
- Locations
- 🇨🇳
First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT04256941
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT04236310
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.